Dextromethorphan


Description

The d-isomer of the codeine analog of levorphanol. Dextromethorphan shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (receptors, N-methyl-D-aspartate) and...

Read more

Pharmacology

Indication

For treatment and relief of dry cough.

Pharmacodynamic

Dextromethorphan suppresses the cough reflex by a direct action on the cough center in the medulla o... Read more

Mechanism of action

Dextromethorphan is an opioid-like drug that binds to and acts as antagonist to the NMDA glutamaterg... Read more

Absorption

Rapidly absorbed from the gastrointestinal tract.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

3-6 hours

Route of elimination

Information currently not available.

Toxicity

Information currently not available.


Adverse Effects

Effect Regions Age Groups Incidences Evidence Type

Contraindications

Information currently not available.

Food Interactions

  • Take without regard to meals.

Interactions

Type in a drug name to check for interaction with Dextromethorphan

The metabolism of (R)-warfarin can be decreased when combined with Dextromethorphan.
The metabolism of (S)-Warfarin can be decreased when combined with Dextromethorphan.
The metabolism of Dextromethorphan can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
The therapeutic efficacy of Dextromethorphan can be decreased when used in combination with 1,10-Phenanthroline.
The risk or severity of serotonin syndrome can be increased when Dextromethorphan is combined with 2,5-Dimethoxy-4-ethylamphetamine.
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Dextromethorphan.
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with 4-Bromo-2,5-dimethoxyamphetamine.
The metabolism of 4-hydroxycoumarin can be decreased when combined with Dextromethorphan.
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with 4-Methoxyamphetamine.
The metabolism of 5-androstenedione can be decreased when combined with Dextromethorphan.
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with 5-methoxy-N,N-dimethyltryptamine.
The metabolism of Dextromethorphan can be decreased when combined with 6-Deoxyerythronolide B.
The metabolism of 6-O-benzylguanine can be decreased when combined with Dextromethorphan.
The metabolism of Dextromethorphan can be decreased when combined with 7-ethyl-10-hydroxycamptothecin.
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with 7-Nitroindazole.
The risk or severity of serotonin syndrome can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Dextromethorphan.
The metabolism of 9-aminocamptothecin can be decreased when combined with Dextromethorphan.
The metabolism of Dextromethorphan can be increased when combined with Abatacept.
The metabolism of Abemaciclib can be decreased when combined with Dextromethorphan.

References

  • 1 . Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, Pope LE, Smith RA: Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology. 2004 Oct 26;63(8):1364-70. [PubMed: 15505150]
  • 2 . Olney JW, Labruyere J, Price MT: Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science. 1989 Jun 16;244(4910):1360-2. [PubMed: 2660263]
  • 3 . Hargreaves RJ, Hill RG, Iversen LL: Neuroprotective NMDA antagonists: the controversy over their potential for adverse effects on cortical neuronal morphology. Acta Neurochir Suppl (Wien). 1994;60:15-9. [PubMed: 7976530]
  • 4 . Carliss RD, Radovsky A, Chengelis CP, O'Neill TP, Shuey DL: Oral administration of dextromethorphan does not produce neuronal vacuolation in the rat brain. Neurotoxicology. 2007 Jul;28(4):813-8. Epub 2007 Apr 6. [PubMed: 17573115]
  • 5 . Hernandez SC, Bertolino M, Xiao Y, Pringle KE, Caruso FS, Kellar KJ: Dextromethorphan and its metabolite dextrorphan block alpha3beta4 neuronal nicotinic receptors. J Pharmacol Exp Ther. 2000 Jun;293(3):962-7. [PubMed: 10869398]

Recent Questions